October 4th 2019
Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Combination of Bleomycin and G-CSF Does Not Increase Risk for Bleomycin-Induced Pulmonary Toxicity
October 18th 2018A study has found no evidence that bleomycin plus granulocyte-stimulating factor (G-CSF) increases the risk for bleomycin-induced pulmonary toxicity in patients with Hodgkin lymphoma.
Read More
Earlier Antipseudomonal De-escalation Is a Possibility in AML, Neutropenia
October 8th 2018Patients with acute myeloid leukemia (AML) and febrile neutropenia that are de-escalated on day 5 if they were afebrile, hemodynamically stable, and without evidence of infection, had similar clinical outcomes and a decreased incidence of Clostridium difficile infections compared with patients without these early on re-evaluations for de-escalation.
Read More
Second Biosimilar Approved to Treat Neutropenia
July 25th 2018A second biosimilar to Amgen’s Neupogen, which treats neutropenia, has been approved in the United States. The FDA approved Pfizer’s filgrastim-aafi, which will be sold under the brand name Nivestym. Zarxio (filgrastim-sndz) was the first filgrastim biosimilar approved by the FDA in 2015.
Read More
Determining Discharge Criteria for Pediatric Patients Admitted With Febrile Neutropenia
December 30th 2017Management of pediatric oncology patients with febrile neutropenia and hospitalization duration currently vary by institution and by provider. A poster presented at the 59th American Society of Hematology Annual Meeting reviewed pediatric hematology/oncology patients who were admitted with febrile neutropenia to determine discharge and release, as well as subsequent readmission within the next 4 days.
Read More
The Relevance of Febrile Neutropenia in Oncology
December 30th 2017Febrile neutropenia (FN) is among the most serious clinical complications in patients with cancer who are undergoing chemotherapy. Patients with neutropenia, or low neutrophil counts, are predisposed to serious and life-threatening infections because of their immune system’s impaired ability to mount inflammatory responses to bacteria, fungi, and yeast.1,2 Because fever is often the only sign of infection in these patients, the presence of both fever and neutropenia must be treated as a medical emergency.2,3 Despite advances in treatment and prevention, mortality rates in patients with cancer and FN can range from 5% to 20%. Higher mortality rates are associated with patients who have higher occurrences of infectious complications and more comorbidities.3 Although there are slightly varying definitions of FN, most clinical guidelines follow the definitions set forth by the Infectious Diseases Society of America (IDSA).4,5 The IDSA defines fever as a single oral temperature ≥38.3°C (101°F) or a temperature ≥38.0°C (100.4°F) lasting more than 1 hour, and defines neutropenia as an absolute neutrophil count (ANC)
Read More
Annual spending on biologic medications has been on the rise. It is estimated that biologic drugs, defined as complex, protein-based, large-molecule compounds designed to treat complicated disease states, accounted for $200 billion to $210 billion of global spending on medicines in 2016.1,2 With such rises in healthcare spending, it is important to consider the economic implications and potential of adopting effective cost-saving measures wherever possible. Biosimilars can offer an opportunity in terms of cost-saving potential, with an estimated potential of $44.2 billion in savings in biologic drug spending in the United States from 2014 to 2024.3 The cost savings could ultimately provide huge benefits to patients, healthcare providers, and all payers involved in the healthcare system, which is especially important in an era of rapidly rising healthcare costs.3 A biosimilar is a biological product that is approved for use based on chemical, molecular, and structural similarities to an already approved biological drug, known as the reference drug or originator product.2 According to the FDA, a biosimilar must show no clinically significant differences in its efficacy and safety profile in comparison with its reference product.4 The introduction of biosimilars into the pharmaceutical market has lowered medication costs while also allowing expanded » patient access to new treatments.5 One example in which the economic and facilitative impact of biosimilars can be seen is the granulocyte colony-stimulating factor (G-CSF) market; there were notable changes in the cost and accessibility of the medication class after the introduction of biosimilars.
Read More
Long-Term Effects of G-CSF Use in Patients With Cyclic Neutropenia
December 26th 2017Based on long-term observations, granulocyte colony-stimulating factor utilization is a safe and effective treatment to prevent infections and improve quality of life in patients with cyclic neutropenia, according to an analysis in The New England Journal of Medicine.
Read More
Diagnosing Congenital Neutropenia
December 23rd 2017Physicians caring for patients with severe congenital neutropenia should be ready to detect issues with multiple systems in the body, explained Seth Corey, MD, of the Virginia Commonwealth University and the Massey Cancer Center & Children's Hospital of Richmond, during a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia.
Read More
Pegfilgrastim Biosimilar Shows Comparability in Pharmacodynamics, Immunogenicity
December 20th 2017There are no clinically meaningful differences in the safety profile of B12019 and pegfilgrastim, according to study findings presented at the American Society of Hematology’s 59th Annual Meeting and Exposition in Atlanta, Georgia.
Read More
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16th 2017In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, Brian Curtis, PhD, of the BloodCenter of Wisconsin Blood Research Institute, highlighted drugs other than chemotherapy that may cause neutropenia in patients.
Read More
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 13th 2017Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival by 5%, although the rates of neutropenia and infections were higher in patients administered the brentuximab-containing regimen.
Read More
Filgrastim and Biosimilar Filgrastim-sndz Equally Efficient in Preventing Febrile Neutropenia
December 6th 2017A study published in the Journal of Managed Care & Specialty Pharmacy found that filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require hospitalization. However, inferiority could not be established for serious adverse events.
Read More
The Optimal Duration of EAT for Patients With Febrile Neutropenia and Hematological Malignancies
December 6th 2017For high-risk patients with hematological malignancies and febrile neutropenia, empirical antimicrobial therapy can be discontinued after 72 hours of apryexia and clinical recovery regardless of their neutrophil count, according to a study in The Lancet Hematology. The traditional approach of continuing the initial regimen of EAT in neutropenic patients with unexplained fever until neutrophil recovery could result in unnecessarily prolonged EAT.
Read More
The Switch From Filgrastim to a Cheaper Alternative: Tbo-Filgrastim
December 1st 2017With the increasing emergence of less expensive biologic alternatives, some health systems are making the switch. For a large healthcare system, the arrival of a cheaper alternative to filgrastim prompted the conversion to using tbo-filgrastim as the preferrred granulocyte-colony stimulating factor. The results were shared in a study published by the Journal of Managed Care & Specialty Pharmacy.
Read More
Dr Kashyap Patel Explains the Risks and Effects of Neutropenia
November 30th 2017In an interview with The American Journal of Managed Care®, Kashyap Patel, MD, Carolina Blood and Cancer Care, discussed risk factors that contribute to the development of neutropenia, how to minimize the risk of development, the effects of neutropenia, and what he recommends to patients who have been treated for the condition.
Read More
Dr David Dale on Neutropenia: Symptoms, Causes, Dangers, and Costs
November 22nd 2017David Dale, MD, professor, internal medicine, University of Washington Medical Center, dicusess diagnosing neutropenia and its symptoms; the causes of neutropenia; when neutropenia becomes dangerous and requires hospitalization; and the costs associated with neutropenia in an interview with The American Journal of Managed Care®.
Read More
Determining the Risk of Chemotherapy-Induced Neutropenia to Guide Use of Colony-Stimulating Factors
November 21st 2017A recent abstract presented at the American Society of Clinical Oncology (ASCO) annual meeting compared 2 risk models for patients with intermediate chemotherapy-induced neutropenia (CIN) risk and compared them to guidelines from ASCO and the National Comprehensive Cancer Network to determine when colony-stimulating factor should be ideally used to prevent CIN. ​​​​​​
Read More
Maximal Tolerated Dose of Hydroxyurea Supported in Children With Sickle Cell Anemia
November 14th 2017Recently reported results from Hydroxyurea Study of Long-Term Effects (HUSTLE) support the use of hydroxyurea in children, and indicate that a preferred dosing strategy should target an HbF endpoint of greater than 20%.
Read More
MSK and PathoQuest Test Method to Detect Infection in Patients With Febrile Neutropenia
November 11th 2017A new collaboration between PathoQuest and Memorial Sloan Kettering Cancer Center (MSK) will test the best method to identify microorganisms responsible for infections in patients with febrile neutropenia.
Read More
Examining Top Reasons for Cancer-Related ED Visits
November 10th 2017While it is known that febrile neutropenia is the most common reason for pediatric patients with cancer visiting the emergency department (ED), little had been known about the most common reasons for adult patients with cancer ending up in the ED.
Read More
Educating Patients About Risk of Febrile Neutropenia Associated With Strong Chemotherapy
October 31st 2017Strong chemotherapy may be part of the treatment plan for patients diagnosed with cancer, but it also comes with risks. A new campaign will empower patients with cancer to better understand and navigate risks such as febrile neutropenia that are associated with strong chemotherapy.
Read More